Martine Rothblatt, an insider at United Therapeutics Corp (UTHR), sold 180 shares of the biotechnology company on November 20, 2025. The shares were sold at a price of $475.42 each, totaling approximately $86,000. Following this transaction, Rothblatt retains 180 shares in the company.
United Therapeutics, headquartered in Silver Spring, Maryland, focuses on the development and commercialization of therapies for patients with chronic and life-threatening conditions. The company employs 1,305 full-time staff and markets various treatments for pulmonary arterial hypertension (PAH), including Tyvaso DPI and Remodulin. The firm also offers oncology products, such as Unituxin for high-risk neuroblastoma.
As of November 20, 2025, United Therapeutics boasts a market capitalization of $20.5 billion, a P/E ratio of 16.13, and an EPS of 26.41. The company has upcoming earnings reports scheduled for April 28, 2026, and July 28, 2026, with estimated EPS of $7.37 and $7.57, respectively.
Insider transactions like Rothblatt's are reported to the SEC, providing transparency into the actions of company executives. While such sales can occur for various personal or financial reasons, they should be viewed in the broader context of insider activity and market conditions rather than as isolated indicators of company performance.